The role of HPVs in benign and malignant cutaneous proliferations

Papillomavirus Report

Volumn 14, Issue 1, 2003, Pages 1-10

  Majewski, Slawomir ^a   Jablonska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

AUTOIMMUNITY; CARCINOGENICITY; CHROMOSOME 17Q; CHROMOSOME 2P; CHROMOSOME MAP; CYTOTOXIC LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENETICS; IMMUNOSURVEILLANCE; NONHUMAN; PATHOGENESIS; PSORIASIS; REVIEW; SKIN CANCER; VIRUS TYPING; WART VIRUS;

ALPHAVIRUS; DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0037233040     PISSN: 09574190     EISSN: None     Source Type: Journal    
DOI: 10.1179/095741903235001650     Document Type: Review

References (82)

1. Williams HC, Pottier A, Strachan D. The descriptive epidermiology of warts in British schoolchildren. Br J Dermatol 1993;128:504-511.
2. Orth G, Favre M, Croissant O. Characterization of a new type of human papillomavirus that causes skin warts. J Virol 1977;76:569-580.
3. Jablonska S, Orth G, Obalek S, Criossant O. Cutaneous warts: clinical, histologic and virologic correlations. In: Warts Human Papillomaviruses. S. Jablonska, G. Orth (eds). Clinics in Dermatology. Philadelphia: Lipincott;1985. Vol. 3:71-82.
4. Gross G, Pfister H, Hagedorn M, Gissmann L. Correlation between human papillomavirus (HPV) type and histology of warts. J Invest Dermatol 1982;78:160-4.
5. Jablonska S, Majewski S, Obalek S, Orth G. Cutaneous warts. Clin Dermatol 1997;15:309-19.
6. Orth G, Favre M. Human papillomaviruses: biochemical and biologic properties. Clin Dermatol 1985;3:27-42.
7. Rosl F, Lengert M, Albrecht J, Kleine K, Zawatzky R, Schraven B, zur Hausen H. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994;68:2142-50.
8. Schröder J-M. Cytokine networks in the skin. J Invest Dermatol 1995;105:20S-24S.
9. Pfister H, zur Hausen H. Seroepidemiological studies of human papillomavirus type 1 (HPV-1) infections. Int J Cancer 1978;21:161-5.
10. Egawa K. New types of human papillomaviruses and intracytoplasmic inclusion bodies: a classification of inclusion warts according to clinical features, histology and associated HPV types. Br J Dermatol 1994;130:158-66.
11. Matsukura T, Iwasaki T, Kawashima M. Molecular cloning of a novel human papillomavirus (type 60) from a plantar cyst with characteristic pathological changes. Virology 1992;190:561-4.
12. Orth G, Jablonska S, Favre M, Croissant O, Obalek S, Jarzabek-Chorzelska M, et al. Identification of papillomaviruses in butcher's warts. J Invest Dermatol 1981;76:97-102.
13. Jablonska S, Obalek S, Favre M, Golebiowska A, Croissant O, Orth G. The morphology of butcher's warts as related to papillomavirus types. Arch Dermatol Res 1987;279 (suppl.):S65-S72.
14. Melchers W, de Mare S, Kuitert E, Galama J, Walboomers J, van den Brule AJ. Human papillomavirus and cutaneous warts in meat handlers. J Clin Microbiol 1993;31:2547-9.
15. Maitland NJ, Keefe M, Al-Ghamdi A, Coggon D. Human papillomavirus type 7 and the butcher's wart. Papillomavirus Rep 1995;6:33-7.
16. De Villiers EM, Neumann C, Oltersdorf T, Fierlbeck G, zur Hausen H. Buchter's wart virus (HPV-7) infections in non-butchers. J Invest Dermatol 1986;87:236-8.
17. Greenspan D, de Villiers EM, Greenspan JSYG, zur Hausen H. Usual HPV types in oral warts in association with HIV infection. J Oral Pathol 1998;17:482-8.
18. De Villiers E-M. Prevalence of HPV-7 papillomaviruses in the oral mucosa and facial skin of patients with human immunodeficiency virus. Arch Dermatol 1989;125:1590.
19. Obalek S, Favre M, Szymanczyk J, Misiewicz J, Jablonska S, Orth G. Human papillomavirus (HPV) types specific of epidermodysplasia verruciformis detected in warts induced by HPV-3 or HPV-3-related types in immunosuppressed patients. J Invest Dermatol 1992;98:936-41.
20. Jablonska S, Dabrowski J, Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of Papovaviruses in oncogenesis. Cancer Res 1972;32:583-9.
21. Orth G. Epidermodysplasia verruciformis. In: Salzman HP, Howley PM, eds. The papillomaviruses. New York, London: Plenum Press;1987:199-43.
22. Orth G, Jablonska S, Favre M, Croissant O, Jarzabek-Chorzelska M, Rzesa G. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci USA 1978;75:1537-41.
23. Orth G, Jablonska S, Jarzabek-Chorzelska M, Obalek S, Rzesa G, Favre M, et al. Characteristics of the lesions and risk of malignant conversion association with the type human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res 1979;39:1074-82.
24. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995;131:1312-8.
25. Lutzner MA. Epidermodysplasia verruciformis: an autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978;65:169-82.
26. Androphy EJ, Dvoretzky J, Lowy DR. X-linked inheritance of epidermodysplasia verruciformis: genetic and virologic studies of a kindred. Arch Dermatol 1985;121:864-8.
27. Ramoz N, Rueda LA, Bouadjar B, Favre M, Orth G. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999;112:259-63.
28. Ramoz N, Taieb A, Rueda LA, Montoya LS, Bouadjar B, Favre M, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J invest Dermatol 2000;114:1148-53.
29. Ramoz N, Rueda LA, Rueda B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nature Genet 2002;32:1-3.
30. Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997;57:4214-6.
31. Majewski S, Skopinska-Rozewska E, Jablonska S, Wasik M, Misiewicz J, Orth G. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986;15:966-73.
32. Jablonska S, Obalek S, Orth G, Haftek M, Jarzabek-Chorzelska M. Regression of the lesions of epidermodysplasia verruciformis. Br J Dermatol 1982;107:109-16.
33. Brash DE. Sunlight and the onset of skin cancer. Trends Genet 1997;13:410-4.
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
35. Padlewska K, Ramoz N, Cassonnet P, Riou G, Barrois M, Majewski S, et al. Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J Invest Dermatol 2001;117:935-42.
36. Yutsudo M., Hakura A. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of patient with epidermodysplasia verruciformis. Int J Cancer 1987; 39:586-9.
37. Elbel M, Carl S, Spaderna S, Iftner T. A comparative analysis of the interactions of the E6 protein from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997;239:132-49.
38. Jackson S, Stanley A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UVA damage. Oncogene 2000;19:592-8.
39. Deau MC, Favre M, Orth G. Genetic heterogeneity among papillomaviruses (HPV) associated with epidermodysplasia verruciformis: Evidence for multiple allelic forms of HPV and HPV-8 E6 genes. Virology 1991;184:492-503.
40. Cooper KD, Androphy EJ, Lowy D, Katz SI. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990;94:769-76.
41. Majewski S, Malejczyk J, Jablonska S, Misiewicz J, Rudnicka L, Obalek S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1990;22:423-7.
42. Jablonska S, Majewski S. Epidermodysplasia verruciformis: immunological and clinical aspects. In: zur Hausen H (ed.). Curr Topics Microbiol Immunol. Berlin, Heidelberg: Springer-Verlag;1994. Vol. 186:157-75.
43. Majewski S, Hunzelmann N, Nischt R, Eckes B, Rudnicka L, Orth G, et al. TGFβ-1 and TNFα expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991;97:862-7.
44. Majewski S, Malejczyk M, Padlewska K, Favre M, Orth G, Jablonska S. Clinical and immunological responses to HPV-5 L1 VLPs in patients with epidermodysplasia verruciformis. International Conference on Papillomaviruses, Paris: Institut Pasteur, 2002.
45. Majewski S, Malejczyk M, Favre M, Orth G, Jablonska S. Cell-mediated immune responses to HPV-5 VLPs and IFN-g production by T-cells from patients with epidermodysplasia verruciformis or psoriasis. International Conference on Papillomaviruses, Paris: Institut Pasteur, 2002.
46. Berkhout RJM, Tieben LM, Smits HL, Bouwes Bavinc JN, Vermeer BJ, ter Schegget J. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;33:690-5.
47. De Villiers EM, Lavargne D, McLaren K, Benton EC. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer 1997;73:358-61.
48. De Jong-Tieben LM, Berkhout RJ, ter Schegget J, Vermeer BJ, de Fijter JW, Bruijn JA, et al. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 2000 Jan 15;69(1):44-9.
49. Harwood CA, Proby ChM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002;15:101-14.
50. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97.
51. Jenson AB, Geyer S, Sundberg JP, Ghim S. Human papillomavirus and skin cancer. J Invest Dermatol Symp Proc 2001;6:203-6.
52. Wieland U, Ritzkowsky A, Stoltidis M, Weissenborn S, Stark S, Ploner M, et al. Papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol 2000;115:124-8.
53. Astori G, Lavergne D, Benton C, Hockmayr B, Egawa K, Garbe C, et al. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 1998;110:752-5.
54. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 2000;74:11636-41.
55. Boxman ILA, Berkhout RJM, Mulder LHC, Wolkers MC, Bouwes-Bavinck JN, Vermeer BJ, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712-5.
56. Boxman IL, Russell A, Mulder LH, Bavinck JN, Schegget JT, Green A. Case control study in subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia human papillomavirus DNA in plucked eyebrow hairs. Int J Cancer 2000;86:110-21.
57. Boxman ILA, Russell A, Mulder LHC, Bouwes Bavnick JN, ter Schegget J, Gree A. Association between epidermodysplasia verruciformis-associated human papillomavirus DNA in plucked eyebrow hairs and solar keratoses. J Invest Dermatol 2001;117:1108-12.
58. Favre M, Majewski S, Noszczyk B, Maienfisch F, Pura A, Orth G, et al. Antibodies to human papillomavirus type 5 are generated in epidermal repair processes. J Invest Dermatol 2000;114:403-7.
59. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998;110:311-7.
60. Weissenborn SJ, Hopfl R, Weber F, Smola H, Pfister HJ, Fuchs PG, et al. High prevalence of a variety of epidermodysplasia veffuciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol 1999;113:122-6.
61. Mahé E, Majewski S, Jablonska S, Orth G, Favre M. High prevalence of antibodies against HPV-5 E6 and E7 oncoproteins in patients with psoriasis. International Conference on Papillomaviruses, Paris: Institut Pasteur, 2002.
62. Iizuka H, Ishida-Yamamoto A, Honda H. Epidermal remodelling in psoriasis. Br J Dermatol 1996;135:433-8.
63. Iizuka H, Ishida-Yamamoto A. Another support for the location of epidermal stem cells residing adjacent to the tips of dermal papillae in the inter follicular epidermis. J Invest Dermatol 1997;109:697.
64. Martin R. Wound healing-aiming for perfect skin regeneration. Science 1997;276:75-81.
65. Jones PH, Harper S, Watt FM. Stem cell patterning and fate in human epidermis. Cell 1995;80:83-93.
66. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T-cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T-cells in psoriatic patients. J Invest Dermatol 1999;113:752-9.
67. Baker BS, Bokth S, Powles A, Garioch JJ, Lewis H, Valdimarsson H, et al. Group A streptococcal antigen specific T lymphocytes in guttate psoriatic lesions. Br J Dermatol 1993;128:493-9.
68. Leung DY, Walsh P, Giorno R, Norris DA. A potential role for superantigens in the pathogenesis of psoriasis. J Invest Dermatol 1993;100:225-8.
69. Davison SC, Allen MH, Mallon E, Barker JNWN. Contrasting patterns of streptococcal superantigen-induced T-cell proliferation in guttate vs. chronic plaque psoriasis. Br J Dermatol 2001;145:245-51.
70. β13.1 genes. Proc Natl Acad Sci USA 1994;91:9282-6.
71. Chang JCC, Smith LR, Froning KJ, Kurland HH, Schwabe BJ, Blumeyer KK, et al. Persistence of T-cell clones in psoriatic lesions. Arch Dermatol 1997;133:703-8.
72. Bour H, Puisieux I, Even J, Kourilsky P, Favrot M, Musette P, et al. T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response. Human Immunol 1999;60:665-76.
73. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest 1999;104:1181-9.
74. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T-cells induces psoriasis. Am J Pathol 1999;155:145-58.
75. Majewski S, Favre M, Orth G, Jablonska S. Is human papillomavirus type 5 the putative autoantigen involved in psoriasis? J Invest Dermatol 1998;111:541.
76. Majewski S, Jablonska S, Favre M, Ramoz M, Orth G. Papillomaviruses and autoimmunity in psoriasis. Immunol Today 1999;20:475-6.
77. Harwood CA, Spink PJ, Surentheran T, Leigh IM, Proby CM, Hawk LM, et al. Epidermodysplasia verruciformis-type human papillomaviruses in PUVA-associated non-melanoma skin cancers. Br J Dermatol 1997;136:445.
78. Bayle-Lebey P, Labadie F, Basset-Seguin N, Bazex J. Carcinomes cutanés et papillomavirus 5: révélation lors d'une photochimiothérapie UVA prolongée. Ann Dermatol Venereol 1994;121:496-8.
79. Nataraj AJ, Black IIS, Ananthaswamy HN. Signature p53 mutations at DNA crosslinking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancer. Proc Natl Acad Sci USA 1996;93:7961-5.
80. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN. p53 mutations in squamous cell carcinomas from psoriasis patients treated with psoralen +UVA (PUVA). J Invest Dermatol 1997;109:238-43.
81. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998;134:595-8.
82. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of human beta - defension-3, a novel human inducible peptide antibiotic. J Biol Chem 2001;276:5707-13.